Literature DB >> 9486038

Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes.

Y S Chen1, S F Hackett, C L Schoenfeld, M A Vinores, S A Vinores, P A Campochiaro.   

Abstract

AIMS/
BACKGROUND: Epiretinal membranes (ERMs) arise from a variety of causes or, in some cases, for unknown reasons. Once established, ERMs tend to progress, becoming more extensive and exerting increasing traction along the inner surface of the retina. One possible cause for their progression is the production of growth factors by cells within ERMs that may provide autocrine or paracrine stimulation. Platelet derived growth factor (PDGF) and its receptors have been localised to cells of ERMs and may play such a role. In this study, comparative data were sought for several other growth factors that have been implicated in ERM formation.
METHODS: Immunohistochemical staining of ERMs was done for PDGF-A, PDGF-B, basic fibroblast growth factor (bFGF), three isoforms of transforming growth factor beta (TGF-beta), and vascular endothelial growth factor (VEGF) and its receptors, flt-1 and flk-1/KDR. Expression of flt-1 and flk-1/KDR was examined in cultured retinal pigmented epithelial (RPE) cells and retinal glia from postmortem eyes by immunohistochemistry and by reverse transcription coupled to polymerase chain reaction (RT-PCR).
RESULTS: Staining was most intense and most frequently observed for VEGF and PDGF-A, both in vascular and avascular ERMs. The majority of cells stained for VEGF in nine of 11 (81.8%) diabetic ERMs and in 14 of 24 (58.3%) proliferative vitreoretinopathy ERMs. The receptors for VEGF, flt-1, and flk-1/KDR were also identified on cells in ERMs and on cultured RPE cells. By RT-PCR, mRNA for flt-1 was identified in RPE cells and retinal glia, and mRNA for flk-1/KDR was identified in RPE cells.
CONCLUSIONS: These data show that VEGF and its receptors are localised to both vascular and avascular ERMs and suggest that VEGF, like PDGF-A, may be an autocrine and paracrine stimulator that may contribute to progression of vascular and avascular ERMs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9486038      PMCID: PMC1722016          DOI: 10.1136/bjo.81.10.919

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  61 in total

1.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

Authors:  A P Adamis; J W Miller; M T Bernal; D J D'Amico; J Folkman; T K Yeo; K T Yeo
Journal:  Am J Ophthalmol       Date:  1994-10-15       Impact factor: 5.258

2.  Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells.

Authors:  D S Charnock-Jones; A M Sharkey; C A Boocock; A Ahmed; R Plevin; N Ferrara; S K Smith
Journal:  Biol Reprod       Date:  1994-09       Impact factor: 4.285

3.  Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.

Authors:  S G Robbins; R N Mixon; D J Wilson; C E Hart; J E Robertson; I Westra; S R Planck; J T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-09       Impact factor: 4.799

4.  Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells.

Authors:  T Takahashi; T Shirasawa; K Miyake; Y Yahagi; N Maruyama; N Kasahara; T Kawamura; O Matsumura; T Mitarai; O Sakai
Journal:  Biochem Biophys Res Commun       Date:  1995-04-06       Impact factor: 3.575

5.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Authors:  E A Pierce; R L Avery; E D Foley; L P Aiello; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

6.  Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy.

Authors:  F Malecaze; S Clamens; V Simorre-Pinatel; A Mathis; P Chollet; C Favard; F Bayard; J Plouet
Journal:  Arch Ophthalmol       Date:  1994-11

7.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.

Authors:  T Cohen; H Gitay-Goren; R Sharon; M Shibuya; R Halaban; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

8.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

9.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

Authors:  J W Miller; A P Adamis; D T Shima; P A D'Amore; R S Moulton; M S O'Reilly; J Folkman; H F Dvorak; L F Brown; B Berse
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells.

Authors:  P A Campochiaro; S F Hackett; S A Vinores; J Freund; C Csaky; W LaRochelle; J Henderer; M Johnson; I R Rodriguez; Z Friedman
Journal:  J Cell Sci       Date:  1994-09       Impact factor: 5.285

View more
  28 in total

Review 1.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

2.  Angiogenic factors in human proliferative sickle cell retinopathy.

Authors:  J Cao; M K Mathews; D S McLeod; C Merges; L M Hjelmeland; G A Lutty
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy.

Authors:  G Smith; D McLeod; D Foreman; M Boulton
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

4.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Subretinal organization in stage 5 retinopathy of prematurity.

Authors:  Scott M Steidl; Tatsuo Hirose
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-18       Impact factor: 3.117

6.  VEGF localisation in diabetic retinopathy.

Authors:  M Boulton; D Foreman; G Williams; D McLeod
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

7.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

8.  PDGF receptors are activated in human epiretinal membranes.

Authors:  Jing Cui; Hetian Lei; Arif Samad; Sreenivasa Basavanthappa; David Maberley; Joanne Matsubara; Andrius Kazlauskas
Journal:  Exp Eye Res       Date:  2008-11-08       Impact factor: 3.467

9.  Ranibizumab for idiopathic epiretinal membranes: A retrospective case series.

Authors:  Marwan A Abouammoh; Michel J Belliveau; David R P Almeida; Jeffrey S Gale; Sanjay Sharma
Journal:  Saudi J Ophthalmol       Date:  2013-01-31

10.  Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities.

Authors:  Dan Yoon; Irene Rusu; Irene Barbazetto
Journal:  Int Ophthalmol       Date:  2013-11-22       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.